Bosutinib | List of Frontiers open access articles

Review

Published on 26 Aug 2024

Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia

in Hematologic Malignancies

Valentín García-Gutiérrez
María Teresa Gómez-Casares
Blanca Xicoy
Felipe Casado-Montero
Guillermo Orti
Pilar Giraldo
Juan Carlos Hernández-Boluda

Frontiers in Oncology

doi 10.3389/fonc.2024.1405467

3,493 views
3 citations

Original Research

Published on 15 Mar 2017

Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis

in Respiratory Physiology and Pathophysiology

Priscila J. Carneiro
Amanda L. Clevelario
Gisele A. Padilha
Johnatas D. Silva
Jamil Z. Kitoko
Priscilla C. Olsen
Vera L. Capelozzi
Patricia R. M. Rocco
Fernanda F. Cruz

Frontiers in Physiology

doi 10.3389/fphys.2017.00159

9,551 views
68 citations

Original Research

Published on 03 Jul 2020

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

in Cardiovascular and Smooth Muscle Pharmacology

Hélène Haguet
Céline Bouvy
Anne-Sophie Delvigne
Elise Modaffari
Adeline Wannez
Pierre Sonveaux
Jean-Michel Dogné
Jonathan Douxfils

Frontiers in Pharmacology

doi 10.3389/fphar.2020.01007

8,990 views
31 citations

Original Research

Published on 29 Jun 2022

A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data

in Pharmacogenetics and Pharmacogenomics

Yueshan Zhao
Yue Wang
Da Yang
Kangho Suh
Min Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.906429

3,415 views
4 citations

Original Research

Published on 30 Jul 2019

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC

in Pharmacology of Anti-Cancer Drugs

Man Yuan
Lin-feng Xu
Juan Zhang
Si-yuan Kong
Man Wu
Yuan-zhi Lao
Hua Zhou
Li Zhang
Hongxi Xu

Frontiers in Oncology

doi 10.3389/fonc.2019.00586

6,316 views
22 citations

Original Research

Published on 04 Mar 2021

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach

in Molecular and Cellular Oncology

Ting-Ting Huang
Xin Wang
Shao-Jia Qiang
Zhen-Nan Zhao
Zhuo-Xun Wu
Charles R. Ashby
Jia-Zhong Li
Zhe-Sheng Chen

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.649434

13,183 views
17 citations

Original Research

Published on 17 Nov 2025

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML

in Hematologic Malignancies

Adrian E. Schroer
Tiffany Javadi
Ankit Mehta
Furkan Torlak
Joseph R. McFarland
Girish Kumar
Alexandre L. da Silva
Jamaal Benjamin
Moaz M. Choudhary
Akram Sadeghi

Frontiers in Oncology

doi 10.3389/fonc.2025.1711453

1,982 views

Brief Research Report

Published on 18 Nov 2025

GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists

in Hematologic Malignancies

Massimo Breccia
Alfonso Piciocchi
Elisabetta Abruzzese
Daniela Cilloni
Fausto Castagnetti
Monica Messina
Stefano Soddu
Barbara Scappini
Uros Markovic
Mario Annunziata

Frontiers in Oncology

doi 10.3389/fonc.2025.1697569

1,419 views

Original Research

Published on 29 Sep 2025

Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports

in Pharmacology of Anti-Cancer Drugs

Ya Liu
Ying Huang
Jincai Guo
Xiang Liu
Yixiang Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1665484

1,721 views

Original Research

Published on 06 Nov 2025

In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR

in Translational Pharmacology

Mihnea Lucian Micu
Simion Florin Cira
Mihnea Zdrenghea
Anca Bojan
Andrada Parvu
Tunde Torok-Vistai
Anca Vasilache
Laura Urian
Bancos Anamaria
Laura Ioana Jimbu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1673056

2,439 views

Articles

Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia

Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML

GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists

Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports

In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR